These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

766 related articles for article (PubMed ID: 10914720)

  • 1. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
    Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
    Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer.
    Bottini A; Berruti A; Bersiga A; Brizzi MP; Allevi G; Bolsi G; Aguggini S; Brunelli A; Betri E; Generali D; Scaratti L; Bertoli G; Alquati P; Dogliotti L
    Clin Cancer Res; 2002 Jun; 8(6):1816-21. PubMed ID: 12060622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP.
    Schneider J; Lucas R; Sánchez J; Ruibal A; Tejerina A; Martín M
    Anticancer Res; 2000; 20(6B):4373-7. PubMed ID: 11205274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial.
    Bottini A; Berruti A; Brizzi MP; Bersiga A; Generali D; Allevi G; Aguggini S; Bolsi G; Bonardi S; Tondelli B; Vana F; Tampellini M; Alquati P; Dogliotti L
    Endocr Relat Cancer; 2005 Jun; 12(2):383-92. PubMed ID: 15947110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.
    Makris A; Powles TJ; Dowsett M; Osborne CK; Trott PA; Fernando IN; Ashley SE; Ormerod MG; Titley JC; Gregory RK; Allred DC
    Clin Cancer Res; 1997 Apr; 3(4):593-600. PubMed ID: 9815725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours.
    Bottini A; Berruti A; Bersiga A; Brunelli A; Brizzi MP; Marco BD; Cirillo F; Bolsi G; Bertoli G; Alquati P; Dogliotti L
    Anticancer Res; 1996; 16(5B):3105-10. PubMed ID: 8920776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
    Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S
    J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression.
    Yang W; Klos KS; Zhou X; Yao J; Yang Y; Smith TL; Shi D; Yu D
    Cancer; 2003 Sep; 98(6):1123-30. PubMed ID: 12973835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy.
    Yang Q; Sakurai T; Yoshimura G; Suzuma T; Umemura T; Nakamura M; Nakamura Y; Mori I; Kakudo K
    Oncol Rep; 2003; 10(1):121-5. PubMed ID: 12469156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
    Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ
    Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer.
    Bottini A; Berruti A; Bersiga A; Brizzi MP; Bruzzi P; Aguggini S; Brunelli A; Bolsi G; Allevi G; Generali D; Betri E; Bertoli G; Alquati P; Dogliotti L
    Br J Cancer; 2001 Oct; 85(8):1106-12. PubMed ID: 11710821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
    Kariya S; Ogawa Y; Nishioka A; Moriki T; Ohnishi T; Ito S; Murata Y; Yoshida S
    Radiat Med; 2005 May; 23(3):189-94. PubMed ID: 15940066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide-based primary (radio-)chemotherapy.
    Prisack HB; Karreman C; Modlich O; Audretsch W; Danae M; Rezai M; Bojar H
    Anticancer Res; 2005; 25(6C):4615-21. PubMed ID: 16334152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
    Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer.
    Generali D; Berruti A; Brizzi MP; Campo L; Bonardi S; Wigfield S; Bersiga A; Allevi G; Milani M; Aguggini S; Gandolfi V; Dogliotti L; Bottini A; Harris AL; Fox SB
    Clin Cancer Res; 2006 Aug; 12(15):4562-8. PubMed ID: 16899602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy.
    Foekens JA; Romain S; Look MP; Martin PM; Klijn JG
    Cancer Res; 2001 Feb; 61(4):1421-5. PubMed ID: 11245445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.